Biopharma Boardroom speaks with Nadia Aelbrecht, Vice President, Head of Infectious Disease at QIAGEN, about rapid diagnostics, antimicrobial resistance and the company’s plans to broaden its infectious disease testing portfolio. ... Read more
Symbiosis Pharmaceutical Services is entering a new phase of growth following a £26 million investment to expand its sterile manufacturing capacity and support larger-scale clinical and commercial programmes. In ... Read more
As advanced therapies move from development towards commercial scale, quality is becoming far more than a regulatory checkpoint. It is increasingly a strategic discipline that must be embedded across product development, manufacturing, techno... Read more
As cell and gene therapies progress towards broader commercialisation, scientific innovation alone is no longer enough. The next generation of therapies must be designed from the outset with potency, manufacturability, scalability, analytical... Read more
HCW Biologics Inc. (the “Company” or “HCW Biologics”), a U.S.-based clinical-stage biopharmaceutical company focused on developing novel fusion immunotherapeutics to treat autoimmune diseases, cancer, and senescence-associat... Read more
Eisai Co., Ltd. and Biogen Inc., announced that once weekly lecanemab-irmb subcutaneous injection (brand name: LEQEMBI IQLIK®) is now available in the U.S. for initiation therapy for early Alzheimer’s disease (AD) in adults with mild cogn... Read more
NanoImaging Services, a cryo-EM CRO, and Proteos, a protein production research partner, have announced the launch of TrueCourse Biosciences, an integrated CRO that brings together advanced capabilities to help pharmaceutical and biotechnolog... Read more
As cell and gene therapies progress towards broader commercialisation, scientific innovation alone is no longer enough. The next generation of therapies must be designed from the outset with potency, manufacturability, scalability, analytical... Read more
© 2026 Biopharma Boardroom. All Rights Reserved.
